{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:02Z","timestamp":1772119382315,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["open access funding"],"award-info":[{"award-number":["open access funding"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["open access funding"],"award-info":[{"award-number":["open access funding"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["open access funding"],"award-info":[{"award-number":["open access funding"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["open access funding"],"award-info":[{"award-number":["open access funding"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00520-025-09189-z","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T17:10:32Z","timestamp":1738429832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palliative patients who may benefit from intranasal delivery of symptomatic drugs: a two-center observational study evaluated the administration of morphine and dexamethasone in Polish hospices"],"prefix":"10.1007","volume":"33","author":[{"given":"Anna","family":"Ingielewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Brunka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Szczupak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"7","key":"9189_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/jpm.2021.0567","volume":"25","author":"S Yilmaz","year":"2022","unstructured":"Yilmaz S, Grudzen CR, Durham DD et al (2022) Palliative care needs and clinical outcomes of patients with advanced cancer in the emergency department. J Palliat Med 25(7):1115\u20131121. https:\/\/doi.org\/10.1089\/jpm.2021.0567","journal-title":"J Palliat Med"},{"issue":"6","key":"9189_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3322\/caac.21727","volume":"72","author":"BE Gould Rothberg","year":"2022","unstructured":"Gould Rothberg BE, Quest TE, Yeung SCJ et al (2022) Oncologic emergencies and urgencies: a comprehensive review. CA Cancer J Clin 72(6):570\u2013593. https:\/\/doi.org\/10.3322\/caac.21727","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"9189_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","volume":"96","author":"TC Ryken","year":"2010","unstructured":"Ryken TC, McDermott M, Robinson PD et al (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):103\u2013114. https:\/\/doi.org\/10.1007\/s11060-009-0057-4","journal-title":"J Neurooncol"},{"issue":"7","key":"9189_CR4","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1007\/s00520-019-05081-9","volume":"28","author":"M Mori","year":"2020","unstructured":"Mori M, Morita T, Matsuda Y et al (2020) How successful are we in relieving terminal dyspnea in cancer patients? A real-world multicenter prospective observational study. Support Care Cancer 28(7):3051\u20133060. https:\/\/doi.org\/10.1007\/s00520-019-05081-9","journal-title":"Support Care Cancer"},{"issue":"7","key":"9189_CR5","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00520-019-05116-1","volume":"28","author":"B Aabom","year":"2020","unstructured":"Aabom B, Laier G, Christensen PL, Karlsson T, Jensen MB, Hedal B (2020) Oral morphine drops for prompt relief of breathlessness in patients with advanced cancer-a randomized, double blinded, crossover trial of morphine sulfate oral drops vs. morphine hydrochloride drops with ethanol (red morphine drops). Support Care Cancer 28(7):3421\u20133428. https:\/\/doi.org\/10.1007\/s00520-019-05116-1","journal-title":"Support Care Cancer"},{"issue":"4","key":"9189_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5055\/jom.2013.0168","volume":"9","author":"H Gamborg","year":"2013","unstructured":"Gamborg H, Riis J, Christrup L, Krantz T (2013) Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases. J Opioid Manag 9(4):269\u2013274. https:\/\/doi.org\/10.5055\/jom.2013.0168","journal-title":"J Opioid Manag"},{"issue":"3","key":"9189_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0885-3924(97)00020-1","volume":"14","author":"M Ashby","year":"1997","unstructured":"Ashby M, Fleming B, Wood M, Somogyi A (1997) Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 14(3):157\u2013167. https:\/\/doi.org\/10.1016\/S0885-3924(97)00020-1","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"9189_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/jpm.2016.0432","volume":"20","author":"Y Matsuda","year":"2017","unstructured":"Matsuda Y, Maeda I, Tachibana K et al (2017) Low-dose morphine for dyspnea in terminally ill patients with idiopathic interstitial pneumonias. J Palliat Med 20(8):879\u2013883. https:\/\/doi.org\/10.1089\/jpm.2016.0432","journal-title":"J Palliat Med"},{"issue":"3","key":"9189_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ahj.2004.06.019","volume":"149","author":"CH Zambroski","year":"2005","unstructured":"Zambroski CH, Moser DK, Roser LP, Heo S, Chung ML (2005) Patients with heart failure who die in hospice. Am Heart J 149(3):558\u2013564. https:\/\/doi.org\/10.1016\/j.ahj.2004.06.019","journal-title":"Am Heart J"},{"issue":"3","key":"9189_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/s0885-3924(02)00487-6","volume":"24","author":"C Gannon","year":"2002","unstructured":"Gannon C, McNamara P (2002) A retrospective observation of corticosteroid use at the end of life in a hospice. J Pain Symptom Manage 24(3):328\u2013334. https:\/\/doi.org\/10.1016\/s0885-3924(02)00487-6","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"9189_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3978\/j.issn.2224-5820.2015.09.01","volume":"4","author":"MN Tsao","year":"2015","unstructured":"Tsao MN (2015) Brain metastases: advances over the decades. Ann Palliat Med 4(4):225\u2013232. https:\/\/doi.org\/10.3978\/j.issn.2224-5820.2015.09.01","journal-title":"Ann Palliat Med"},{"issue":"1","key":"9189_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-684X-13-7","volume":"13","author":"A Denton","year":"2014","unstructured":"Denton A, Shaw J (2014) Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand. BMC Palliat Care 13(1):7. https:\/\/doi.org\/10.1186\/1472-684X-13-7","journal-title":"BMC Palliat Care"},{"issue":"3","key":"9189_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/bmjspcare-2015-001037","volume":"6","author":"Y Hatano","year":"2016","unstructured":"Hatano Y, Moroni M, Wilcock A et al (2016) Pharmacovigilance in hospice\/palliative care: the net immediate and short-term effects of dexamethasone for anorexia. BMJ Support Palliat Care 6(3):331\u2013337. https:\/\/doi.org\/10.1136\/bmjspcare-2015-001037","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"9189_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1634\/theoncologist.2014-0260","volume":"21","author":"S Yennurajalingam","year":"2016","unstructured":"Yennurajalingam S, Williams JL, Chisholm G, Bruera E (2016) Effects of dexamethasone and placebo on symptom clusters in advanced cancer patients: a preliminary report. Oncologist 21(3):384\u2013390. https:\/\/doi.org\/10.1634\/theoncologist.2014-0260","journal-title":"Oncologist"},{"issue":"2","key":"9189_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-019-03238-4","volume":"144","author":"CAC Jessurun","year":"2019","unstructured":"Jessurun CAC, Hulsbergen AFC, Cho LD, Aglio LS, Nandoe Tewarie RDS, Broekman MLD (2019) Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? J Neurooncol 144(2):249\u2013264. https:\/\/doi.org\/10.1007\/s11060-019-03238-4","journal-title":"J Neurooncol"},{"issue":"3","key":"9189_CR16","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00520-021-06694-9","volume":"30","author":"APM Jones","year":"2022","unstructured":"Jones APM, McGauran MFG, Jagasia N, Hiscock RJ, Hyde S, Grant P (2022) Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer. Support Care Cancer 30(3):2821\u20132827. https:\/\/doi.org\/10.1007\/s00520-021-06694-9","journal-title":"Support Care Cancer"},{"issue":"2","key":"9189_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21037\/apm-23-537","volume":"13","author":"CT Nguyen","year":"2024","unstructured":"Nguyen CT, McPherson ML, Noble BN, Furuno JP (2024) Prevalence and characteristics of patients prescribed opioids and central nervous system depression agents on discharge to hospice care. Ann Palliat Med 13(2):240\u2013248. https:\/\/doi.org\/10.21037\/apm-23-537","journal-title":"Ann Palliat Med"},{"issue":"1","key":"9189_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12904-020-00681-3","volume":"19","author":"P F\u00fcrst","year":"2020","unstructured":"F\u00fcrst P, Lundstr\u00f6m S, Klepstad P, Strang P (2020) Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 19(1):172. https:\/\/doi.org\/10.1186\/s12904-020-00681-3","journal-title":"BMC Palliat Care"},{"issue":"10","key":"9189_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.12968\/ijpn.2010.16.10.79213","volume":"16","author":"J Walker","year":"2010","unstructured":"Walker J, Lane P, McKenzie C (2010) Evidence-based practice guidelines: a survey of subcutaneous dexamethasone administration. Int J Palliat Nurs 16(10):494\u2013498. https:\/\/doi.org\/10.12968\/ijpn.2010.16.10.79213","journal-title":"Int J Palliat Nurs"},{"issue":"3","key":"9189_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bmjspcare-2019-002029","volume":"10","author":"P Perkins","year":"2020","unstructured":"Perkins P, Parkinson A, Akyea RK, Husbands E (2020) Nasal fentanyl alone plus buccal midazolam: an open-label, randomised, controlled feasibility study in the dying. BMJ Support Palliat Care 10(3):300\u2013303. https:\/\/doi.org\/10.1136\/bmjspcare-2019-002029","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"9189_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/pharmaceutics15030746","volume":"15","author":"R Maher","year":"2023","unstructured":"Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A (2023) Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics 15(3):746. https:\/\/doi.org\/10.3390\/pharmaceutics15030746","journal-title":"Pharmaceutics"},{"key":"9189_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.addr.2020.10.018","volume":"160","author":"JKW Lam","year":"2020","unstructured":"Lam JKW, Cheung CCK, Chow MYT et al (2020) Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Adv Drug Deliv Rev 160:234\u2013243. https:\/\/doi.org\/10.1016\/j.addr.2020.10.018","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"9189_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/pharmaceutics15010207","volume":"15","author":"VA Duong","year":"2023","unstructured":"Duong VA, Nguyen TTL, Maeng HJ (2023) Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics 15(1):207. https:\/\/doi.org\/10.3390\/pharmaceutics15010207","journal-title":"Pharmaceutics"},{"issue":"3","key":"9189_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pharmaceutics14030629","volume":"14","author":"TP Crowe","year":"2022","unstructured":"Crowe TP, Hsu WH (2022) Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics 14(3):629. https:\/\/doi.org\/10.3390\/pharmaceutics14030629","journal-title":"Pharmaceutics"},{"issue":"4","key":"9189_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/pharmaceutics16040519","volume":"16","author":"A Ingielewicz","year":"2024","unstructured":"Ingielewicz A, Szymczak RK (2024) Intranasal therapy in palliative care Pharmaceutics 16(4):519. https:\/\/doi.org\/10.3390\/pharmaceutics16040519","journal-title":"Pharmaceutics"},{"issue":"1","key":"9189_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12904-018-0361-x","volume":"17","author":"L Pieper","year":"2018","unstructured":"Pieper L, Wager J, Zernikow B (2018) Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions. BMC Palliat Care 17(1):106. https:\/\/doi.org\/10.1186\/s12904-018-0361-x","journal-title":"BMC Palliat Care"},{"key":"9189_CR27","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/CMAR.S179012","volume":"11","author":"W Piotrowska","year":"2019","unstructured":"Piotrowska W, Leppert W, Majkowicz M (2019) Comparison of analgesia, adverse effects, and quality of life in cancer patients during treatment of procedural pain with intravenous morphine, fentanyl nasal spray, and fentanyl buccal tablets. Cancer Manag Res 11:1587\u20131600. https:\/\/doi.org\/10.2147\/CMAR.S179012","journal-title":"Cancer Manag Res"},{"issue":"4","key":"9189_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/bmjspcare-2020-002729","volume":"11","author":"P Perkins","year":"2021","unstructured":"Perkins P, Parkinson A, Taylor V, Husbands E (2021) Nasal fentanyl and buccal midazolam carer administration \u201cas needed\u201d for breakthrough symptom control in a specialist palliative care unit: a nested qualitative study. BMJ Support Palliat Care 11(4):440\u2013443. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002729","journal-title":"BMJ Support Palliat Care"},{"issue":"10","key":"9189_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2174\/1567201816666191029122740","volume":"16","author":"K Kashyap","year":"2019","unstructured":"Kashyap K, Shukla R (2019) Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges. Curr Drug Deliv 16(10):887\u2013901. https:\/\/doi.org\/10.2174\/1567201816666191029122740","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"9189_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15360288.2022.2028955","volume":"36","author":"TG Nicholas","year":"2022","unstructured":"Nicholas TG, Husbands EL (2022) Benefits of intranasal administration of diamorphine and midazolam in the management of patients receiving palliative care in the community: a case series. J Pain Palliat Care Pharmacother 36(1):34\u201339. https:\/\/doi.org\/10.1080\/15360288.2022.2028955","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"3","key":"9189_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/bmjspcare-2020-002784","volume":"12","author":"AE Sutherland","year":"2022","unstructured":"Sutherland AE, Presland M, Harrop E, Carey M, Miller M, Wong ICKC (2022) Orodispersible and transmucosal alternative medications for symptom control in adults. BMJ Support Palliat Care 12(3):305\u2013315. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002784","journal-title":"BMJ Support Palliat Care"},{"key":"9189_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155\u2013170. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.10.009","journal-title":"Brain Res Bull"},{"issue":"1","key":"9189_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12904-022-00951-2","volume":"21","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Harrop E, Liossi C et al (2022) Carer preferences of route of administration of transmucosal diamorphine and willingness to take part in a randomised controlled trial: an interview study (DIPPER). BMC Palliat Care 21(1):78. https:\/\/doi.org\/10.1186\/s12904-022-00951-2","journal-title":"BMC Palliat Care"},{"key":"9189_CR34","doi-asserted-by":"publisher","unstructured":"Gastine S, Morse JD, Leung MT, et al. (2022) Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review. BMJ Support Palliat Care.\u00a0https:\/\/doi.org\/10.1136\/bmjspcare-2021-003461","DOI":"10.1136\/bmjspcare-2021-003461"},{"issue":"1","key":"9189_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/pharmaceutics15010105","volume":"15","author":"G C\u00e1rdenas","year":"2022","unstructured":"C\u00e1rdenas G, Bobes RJ, Fragoso G et al (2022) Pharmacokinetic study of intranasal dexamethasone and methylprednisolone compared with intravenous administration: two open-label, single-dose, two-period, two-sequence, cross-over study in healthy volunteers. Pharmaceutics 15(1):105. https:\/\/doi.org\/10.3390\/pharmaceutics15010105","journal-title":"Pharmaceutics"},{"issue":"1","key":"9189_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13063-022-06075-5","volume":"23","author":"G C\u00e1rdenas","year":"2022","unstructured":"C\u00e1rdenas G, Ch\u00e1vez-Canales M, Espinosa AM et al (2022) Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients. Trials 23(1):148. https:\/\/doi.org\/10.1186\/s13063-022-06075-5","journal-title":"Trials"},{"issue":"6","key":"9189_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"21","key":"9189_CR38","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3390\/healthcare11212867","volume":"11","author":"YS Liao","year":"2023","unstructured":"Liao YS, Tsai WC, Chiu LT, Kung PT (2023) Effects of the time of hospice and palliative care enrollment before death on morphine, length of stay, and healthcare expense in patients with cancer in Taiwan. Healthcare (Basel) 11(21):2867. https:\/\/doi.org\/10.3390\/healthcare11212867","journal-title":"Healthcare (Basel)"},{"issue":"12","key":"9189_CR39","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s00520-018-4339-2","volume":"26","author":"Y Hatano","year":"2018","unstructured":"Hatano Y, Matsuoka H, Lam L, Currow DC (2018) Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer 26(12):3979\u20133983. https:\/\/doi.org\/10.1007\/s00520-018-4339-2","journal-title":"Support Care Cancer"},{"issue":"2","key":"9189_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1191\/0269216304pm852oa","volume":"18","author":"F Nauck","year":"2004","unstructured":"Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100\u2013107. https:\/\/doi.org\/10.1191\/0269216304pm852oa","journal-title":"Palliat Med"},{"issue":"1","key":"9189_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpainsymman.2023.09.021","volume":"67","author":"AW An","year":"2024","unstructured":"An AW, Chen X, Urbauer DL, Bruera E, Hui D (2024) Impact of dosing and duration of dexamethasone on serious corticosteroid-related adverse events. J Pain Symptom Manage 67(1):59\u201368. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.09.021","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"9189_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/jpm.2011.0513","volume":"15","author":"J Pilkey","year":"2012","unstructured":"Pilkey J, Streeter L, Beel A, Hiebert T, Li X (2012) Corticosteroid-induced diabetes in palliative care. J Palliat Med 15(6):681\u2013689. https:\/\/doi.org\/10.1089\/jpm.2011.0513","journal-title":"J Palliat Med"},{"issue":"5","key":"9189_CR43","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/j.jpainsymman.2022.07.006","volume":"64","author":"U Wernli","year":"2022","unstructured":"Wernli U, D\u00fcrr F, Jean-Petit-Matile S, Kobleder A, Meyer-Massetti C (2022) Subcutaneous drugs and off-label use in hospice and palliative care: a scoping review. J Pain Symptom Manage 64(5):e250\u2013e259. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.07.006","journal-title":"J Pain Symptom Manage"},{"issue":"e6","key":"9189_CR44","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1136\/bmjspcare-2020-002202","volume":"12","author":"I Murphy","year":"2022","unstructured":"Murphy I, Sivashankar A, Gadoud A (2022) Refractory angina is a growing challenge for palliative medicine: a systematic review of non-invasive interventions. BMJ Support Palliat Care 12(e6):e869\u2013e881. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002202","journal-title":"BMJ Support Palliat Care"},{"issue":"4","key":"9189_CR45","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ajh.26837","volume":"98","author":"CA Rees","year":"2023","unstructured":"Rees CA, Brousseau DC, Ahmad FA et al (2023) Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: a multicenter pediatric emergency medicine perspective. Am J Hematol 98(4):620\u2013627. https:\/\/doi.org\/10.1002\/ajh.26837","journal-title":"Am J Hematol"},{"issue":"5","key":"9189_CR46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00520-014-2491-x","volume":"23","author":"S Mercadante","year":"2015","unstructured":"Mercadante S, Vellucci R, Cuomo A et al (2015) Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer 23(5):1349\u20131354. https:\/\/doi.org\/10.1007\/s00520-014-2491-x","journal-title":"Support Care Cancer"},{"issue":"7","key":"9189_CR47","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s00520-016-3125-2","volume":"24","author":"J Hardy","year":"2016","unstructured":"Hardy J, Randall C, Pinkerton E, Flatley C, Gibbons K, Allan S (2016) A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. Support Care Cancer 24(7):3069\u20133076. https:\/\/doi.org\/10.1007\/s00520-016-3125-2","journal-title":"Support Care Cancer"},{"issue":"4","key":"9189_CR48","doi-asserted-by":"publisher","first-page":"taad026","DOI":"10.1093\/jtm\/taad026","volume":"30","author":"RK Szymczak","year":"2023","unstructured":"Szymczak RK, Sawicka M (2023) Can intranasal delivery of dexamethasone facilitate the management of severe altitude disease? J Travel Med 30(4):taad026. https:\/\/doi.org\/10.1093\/jtm\/taad026","journal-title":"J Travel Med"},{"key":"9189_CR49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3389\/fneur.2018.00595","volume":"9","author":"W Gr\u00f6nheit","year":"2018","unstructured":"Gr\u00f6nheit W, Popkirov S, Wehner T, Schlegel U, Wellmer J (2018) Practical management of epileptic seizures and status epilepticus in adult palliative care patients. Front Neurol 9:595. https:\/\/doi.org\/10.3389\/fneur.2018.00595","journal-title":"Front Neurol"},{"issue":"6","key":"9189_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1177\/02692163211008737","volume":"35","author":"L Jamieson","year":"2021","unstructured":"Jamieson L, Harrop E, Johnson M et al (2021) Healthcare professionals\u2019 views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: a focus group study (DIPPER). Palliat Med 35(6):1118\u20131125. https:\/\/doi.org\/10.1177\/02692163211008737","journal-title":"Palliat Med"},{"issue":"5","key":"9189_CR51","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jpainsymman.2020.11.003","volume":"61","author":"S Iupati","year":"2021","unstructured":"Iupati S, Bridge R, Allan S, Hewitt D (2021) Intranasal fentanyl versus placebo for treatment of episodic breathlessness in hospice patients with advanced nonmalignant diseases. J Pain Symptom Manage 61(5):1035\u20131041. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.11.003","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"9189_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40266-023-01027-3","volume":"40","author":"N Dieudonn\u00e9 Rahm","year":"2023","unstructured":"Dieudonn\u00e9 Rahm N, Zaccaria I, Gil Wey B, Pautex S, Habre W, Elia N (2023) Intranasal dexmedetomidine for pain management in older patients: a cross-over, randomized, double-blinded, active-controlled trial. Drugs Aging 40(6):527\u2013538. https:\/\/doi.org\/10.1007\/s40266-023-01027-3","journal-title":"Drugs Aging"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09189-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:42:14Z","timestamp":1739493734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09189-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9189"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09189-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5271335\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The paper was approved by the Bioethical Committee of Medical University of Gdansk (consent KB\/12\/2024). The ethical standard according to which the study was conducted: The Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"140"}}